Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2011-05-31
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
NCT01098981
Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients
NCT02907736
Pulse Endovascular ReperFUSION for Acute Ischemic Stroke
NCT06052969
Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke
NCT00507806
THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
NCT02002325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute ischemic stroke patients
All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
Computed tomography perfusion imaging
As per standard of care at CPMC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computed tomography perfusion imaging
As per standard of care at CPMC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years old
* presentation up to 6 hours from time of onset of acute stroke symptoms
Exclusion Criteria
* inability to receive CT scan
* allergy to IV contrast
* symptoms with full resolution
* intracerebral hemorrhage
* severe stroke which is classified as 'malignant' (hypodensity on noncontrast CT greater than 1/3 cerebral hemisphere)
* premorbid mRS of \>3
* life expectancy of ≤3 months
* any condition which, in the opinion of the investigator makes the subject unsuitable for study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
California Pacific Medical Center
OTHER
California Pacific Medical Center Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nobl Barazangi
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nobl Barazangi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
CPMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Pacific Medical Center
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PERFUSE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.